Bristol-Myers Squibb: to work with Presage on cancer drugs
(CercleFinance.com) - Bristol-Myers Squibb has struck a collaboration deal with Presage Biosciences, a cancer biotechnology firm, to assess early stage oncology targets in "Phase 0" trials.
The research collaboration will be based on Presage's platform, that enables intratumoral microdosing and an analysis of multiple cancer agents, the companies said.
Presage's approach is intended to rapidly evaluate drug candidates.
The financial terms of the collaboration were not disclosed.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The research collaboration will be based on Presage's platform, that enables intratumoral microdosing and an analysis of multiple cancer agents, the companies said.
Presage's approach is intended to rapidly evaluate drug candidates.
The financial terms of the collaboration were not disclosed.
Copyright (c) 2019 CercleFinance.com. All rights reserved.